-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Benzinga·11/04/2026 20:50:03
Diffusion vocale
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $38.